# A Trial in Healthy Adult Participants and Adults With Autoimmune Disease to Test How HBM7020 is Tolerated and Absorbed in the Body

> **NCT07649265** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 63 (estimated)

## Conditions studied

- Rheumatoid Arthritis
- Systemic Lupus Erythematosus
- Systemic Sclerosis
- Sjögren's Disease

## Interventions

- **DRUG:** HBM7020

## Key facts

- **NCT ID:** NCT07649265
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-15
- **Primary completion:** 2028-11-20
- **Final completion:** 2028-11-20
- **Target enrollment:** 63 (ESTIMATED)
- **Last updated:** 2026-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07649265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07649265, "A Trial in Healthy Adult Participants and Adults With Autoimmune Disease to Test How HBM7020 is Tolerated and Absorbed in the Body". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07649265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*